We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Voyager Therapeutics Inc | NASDAQ:VYGR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.14 | 1.59% | 8.95 | 8.94 | 8.95 | 8.97 | 8.65 | 8.90 | 176,022 | 17:13:28 |
From May 2021 to May 2024
SNO Oral Presentation Details: Title: AAV mediated brain delivery of an ADCC-enhanced antibody obviates xenograft growth in mouse models of HER2+ breast cancer brain metastasisAbstract Number: EXTH-02Abstract Session: CNS MetastasesPresenter: Dan R. Laks, Ph.D., Scientist II, Voyager TherapeuticsPresentation Time: 4:15 p.m. ET
About Voyager TherapeuticsVoyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACERTM screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurologic disorders and other therapeutic areas. voyagertherapeutics.com LinkedIn Twitter
Voyager Contacts Investors Investors@voyagertherapeutics.com Media Scott Santiamo ssantiamo@vygr.com
1 Year Voyager Therapeutics Chart |
1 Month Voyager Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
